Objective sputum colour assessment and clinical outcomes in bronchiectasis : data from the European Bronchiectasis Registry (EMBARC)
Copyright ©The authors 2024..
BACKGROUND: A validated 4-point sputum colour chart can be used to objectively evaluate the levels of airway inflammation in bronchiectasis patients. In the European Bronchiectasis Registry (EMBARC), we tested whether sputum colour would be associated with disease severity and clinical outcomes.
METHODS: We used a prospective, observational registry of adults with bronchiectasis conducted in 31 countries. Patients who did not produce spontaneous sputum were excluded from the analysis. The Murray sputum colour chart was used at baseline and at follow-up visits. Key outcomes were frequency of exacerbations, hospitalisations for severe exacerbations and mortality during up to 5-year follow-up.
RESULTS: 13 484 patients were included in the analysis. More purulent sputum was associated with lower forced expiratory volume in 1 s (FEV1), worse quality of life, greater bacterial infection and a higher bronchiectasis severity index. Sputum colour was strongly associated with the risk of future exacerbations during follow-up. Compared to patients with mucoid sputum (reference group), patients with mucopurulent sputum experienced significantly more exacerbations (incident rate ratio (IRR) 1.29, 95% CI 1.22-1.38; p<0.0001), while the rates were even higher for patients with purulent (IRR 1.55, 95% CI 1.44-1.67; p<0.0001) and severely purulent sputum (IRR 1.91, 95% CI 1.52-2.39; p<0.0001). Hospitalisations for severe exacerbations were also associated with increasing sputum colour with rate ratios, compared to patients with mucoid sputum, of 1.41 (95% CI 1.29-1.56; p<0.0001), 1.98 (95% CI 1.77-2.21; p<0.0001) and 3.05 (95% CI 2.25-4.14; p<0.0001) for mucopurulent, purulent and severely purulent sputum, respectively. Mortality was significantly increased with increasing sputum purulence, hazard ratio 1.12 (95% CI 1.01-1.24; p=0.027), for each increment in sputum purulence.
CONCLUSION: Sputum colour is a simple marker of disease severity and future risk of exacerbations, severe exacerbations and mortality in patients with bronchiectasis.
| Errataetall: |
CommentIn: Eur Respir J. 2024 Apr 18;63(4):. - PMID 38636972 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
The European respiratory journal - 63(2024), 4 vom: 11. Apr. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 22.04.2024 Date Revised 25.04.2024 published: Electronic-Print CommentIn: Eur Respir J. 2024 Apr 18;63(4):. - PMID 38636972 Citation Status MEDLINE |
|---|
| doi: |
10.1183/13993003.01554-2023 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370984072 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370984072 | ||
| 003 | DE-627 | ||
| 005 | 20240425234117.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1183/13993003.01554-2023 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM370984072 | ||
| 035 | |a (NLM)38609095 | ||
| 035 | |a (PII)2301554 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aliberti, Stefano |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Objective sputum colour assessment and clinical outcomes in bronchiectasis |b data from the European Bronchiectasis Registry (EMBARC) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a CommentIn: Eur Respir J. 2024 Apr 18;63(4):. - PMID 38636972 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright ©The authors 2024. | ||
| 520 | |a BACKGROUND: A validated 4-point sputum colour chart can be used to objectively evaluate the levels of airway inflammation in bronchiectasis patients. In the European Bronchiectasis Registry (EMBARC), we tested whether sputum colour would be associated with disease severity and clinical outcomes | ||
| 520 | |a METHODS: We used a prospective, observational registry of adults with bronchiectasis conducted in 31 countries. Patients who did not produce spontaneous sputum were excluded from the analysis. The Murray sputum colour chart was used at baseline and at follow-up visits. Key outcomes were frequency of exacerbations, hospitalisations for severe exacerbations and mortality during up to 5-year follow-up | ||
| 520 | |a RESULTS: 13 484 patients were included in the analysis. More purulent sputum was associated with lower forced expiratory volume in 1 s (FEV1), worse quality of life, greater bacterial infection and a higher bronchiectasis severity index. Sputum colour was strongly associated with the risk of future exacerbations during follow-up. Compared to patients with mucoid sputum (reference group), patients with mucopurulent sputum experienced significantly more exacerbations (incident rate ratio (IRR) 1.29, 95% CI 1.22-1.38; p<0.0001), while the rates were even higher for patients with purulent (IRR 1.55, 95% CI 1.44-1.67; p<0.0001) and severely purulent sputum (IRR 1.91, 95% CI 1.52-2.39; p<0.0001). Hospitalisations for severe exacerbations were also associated with increasing sputum colour with rate ratios, compared to patients with mucoid sputum, of 1.41 (95% CI 1.29-1.56; p<0.0001), 1.98 (95% CI 1.77-2.21; p<0.0001) and 3.05 (95% CI 2.25-4.14; p<0.0001) for mucopurulent, purulent and severely purulent sputum, respectively. Mortality was significantly increased with increasing sputum purulence, hazard ratio 1.12 (95% CI 1.01-1.24; p=0.027), for each increment in sputum purulence | ||
| 520 | |a CONCLUSION: Sputum colour is a simple marker of disease severity and future risk of exacerbations, severe exacerbations and mortality in patients with bronchiectasis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Embarc |2 NLM | |
| 650 | 7 | |a Calcium Phosphates |2 NLM | |
| 700 | 1 | |a Ringshausen, Felix C |e verfasserin |4 aut | |
| 700 | 1 | |a Dhar, Raja |e verfasserin |4 aut | |
| 700 | 1 | |a Haworth, Charles S |e verfasserin |4 aut | |
| 700 | 1 | |a Loebinger, Michael R |e verfasserin |4 aut | |
| 700 | 1 | |a Dimakou, Katerina |e verfasserin |4 aut | |
| 700 | 1 | |a Crichton, Megan L |e verfasserin |4 aut | |
| 700 | 1 | |a De Soyza, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Vendrell, Montse |e verfasserin |4 aut | |
| 700 | 1 | |a Burgel, Pierre-Regis |e verfasserin |4 aut | |
| 700 | 1 | |a McDonnell, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Skrgat, Sabina |e verfasserin |4 aut | |
| 700 | 1 | |a Maiz Carro, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a de Roux, Andres |e verfasserin |4 aut | |
| 700 | 1 | |a Sibila, Oriol |e verfasserin |4 aut | |
| 700 | 1 | |a Bossios, Apostolos |e verfasserin |4 aut | |
| 700 | 1 | |a van der Eerden, Menno |e verfasserin |4 aut | |
| 700 | 1 | |a Kauppi, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Milenkovic, Branislava |e verfasserin |4 aut | |
| 700 | 1 | |a Menendez, Rosario |e verfasserin |4 aut | |
| 700 | 1 | |a Murris, Marlene |e verfasserin |4 aut | |
| 700 | 1 | |a Borekci, Sermin |e verfasserin |4 aut | |
| 700 | 1 | |a Munteanu, Oxana |e verfasserin |4 aut | |
| 700 | 1 | |a Obradovic, Dusanka |e verfasserin |4 aut | |
| 700 | 1 | |a Nowinski, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Amorim, Adelina |e verfasserin |4 aut | |
| 700 | 1 | |a Torres, Antoni |e verfasserin |4 aut | |
| 700 | 1 | |a Lorent, Natalie |e verfasserin |4 aut | |
| 700 | 1 | |a Van Braeckel, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Altenburg, Josje |e verfasserin |4 aut | |
| 700 | 1 | |a Shoemark, Amelia |e verfasserin |4 aut | |
| 700 | 1 | |a Shteinberg, Michal |e verfasserin |4 aut | |
| 700 | 1 | |a Boersma, Wim |e verfasserin |4 aut | |
| 700 | 1 | |a Goeminne, Pieter C |e verfasserin |4 aut | |
| 700 | 1 | |a Elborn, J Stuart |e verfasserin |4 aut | |
| 700 | 1 | |a Hill, Adam T |e verfasserin |4 aut | |
| 700 | 1 | |a Welte, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Blasi, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Polverino, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Chalmers, James D |e verfasserin |4 aut | |
| 700 | 0 | |a EMBARC Registry Investigators |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The European respiratory journal |d 1989 |g 63(2024), 4 vom: 11. Apr. |w (DE-627)NLM012664782 |x 1399-3003 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2024 |g number:4 |g day:11 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1183/13993003.01554-2023 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2024 |e 4 |b 11 |c 04 | ||